Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Valeant reports ‘encouraging’ phase IIb taribavirin results

Valeant reports ‘encouraging’ phase IIb taribavirin results

18th March 2008

Valeant Pharmaceuticals has announced the results of the phase IIb clinical trial of taribavirin at its week-12 treatment analysis point, with the firm reporting that the results at this stage are “encouraging” for the compound.

The antiviral drug is a prodrug of ribavirin which is currently in development as a treatment of chronic hepatitis C administered together with a pegylated interferon.

In the 12-week early viral response analysis, comparable reductions in viral load were observed for weight-based doses of taribavirin and ribavirin, while the anaemia rate in the 20mg/kg and 25mg/kg taribavirin arms were significantly lower than that seen in the ribavirin control arm.

Fred Poordad, chief of hepatology at the Centre for Liver Disease and Transplant at Cedars-Sinai Medical Centre is Los Angeles, said: “Ribavirin continues to be a necessary part of hepatitis C treatment, and clinicians would welcome a ribavirin prodrug with a profile of similar efficacy with decreased anaemia.”

He added that medication with a reduced need for adjunctive growth factor therapy or fewer required dose reductions for anaemia may improve overall response rate and treatment adherence.

In March 2007, Valeant expressed the hope that this phase IIb study would provide the firm with sufficient data to establish the process for registering the compound as a treatment for hepatitis C.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.